Inclusion Criteria:

          -  Histologically or cytologically confirmed malignancy that is metastatic or
             unresectable,

               -  who have progressed to standard therapy,

               -  who are receiving a standard anticancer treatment but no subsequent approved
                  treatment would be available upon progression,

               -  who are unable to receive standard therapy, or

               -  for whom standard therapy does not exist

          -  ECOG performance status of 0 or 1.

          -  18 year-old or older.

          -  Measurable disease according to RECIST 1.1.

          -  Enough tumor tissue for molecular analysis

          -  Patients providing formalin-fixed paraffin embedded tissue (FFPE) must provide a
             minimum amount of tissue ranging from 20 to 28 slides depending on the sample tumor
             cellularity. If there is not enough archival tissue to meet this criterion, the
             patient must undergo a tumor biopsy.

          -  Patients providing fresh frozen tissue must provide 4 core biopsies or equivalent.
             Fresh frozen tissue must be preferentially collected from a tumor biopsy; hence,
             patients must have disease amenable to be biopsied. Otherwise, the patient should have
             fresh frozen tumor tissue stored in a biobank or biorepository.

          -  Efforts will be made to provide fresh frozen tissue in at least one quarter of the
             participating patients.

               -  The proportion of patients that might provide fresh frozen tissue might change
                  based on the results from the molecular analysis.

          -  Since some of the tests are performed in FFPE tissue, patients providing fresh frozen
             tissue from a recent biopsy will have part of the sample processed in formalin-fixed
             paraffin embedded tissue (FFPE) as per Laboratory manual.

          -  Adequate hematological, renal and hepatic function:

          -  For patients requiring a tumor biopsy, patients must have adequate coagulation
             function

               -  Quick time ≥ 60%

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Known brain metastases or leptomeningeal disease

          -  Spinal cord compression not definitively treated with surgery and/or radiation.

          -  Uncontrolled intercurrent illness including, but not limited to, active infection,
             symptomatic congestive heart failure, LVEF < 50%, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Inability to swallow tablets or capsules

          -  Known HIV, hepatitis B or hepatitis C infection.

          -  Known history of malabsorption.

          -  Pregnant and lactating women